Gene Network Sciences Announces Cancer Collaboration with University of Connecticut Health Center's Neag Comprehensive Cancer Center
Posted on: Wednesday, 3 June 2009, 06:00 CDT
GNS and the Neag Comprehensive Cancer Center began their collaboration as a result of a connection made last year between two
"With ever-increasing quantities of molecular and genetic data from cancer patients becoming available, we as clinicians are in great need of capabilities to optimally and rapidly utilize this information," said Dr. Runowicz. "We are excited to link up with GNS, which has created a unique supercomputer-driven technology platform to turn this information directly into simulation models, and ultimately better treatments, for cancer patients."
The parties will utilize the Neag Comprehensive Cancer Center's clinical expertise to assess and validate findings from the ovarian cancer model simulations and will work with strategic partners to make drugs and diagnostics created based on these discoveries available to patients. They are also currently in discussions regarding the application of the REFS(TM) platform in other cancers such as prostate cancer.
"GNS is looking forward to working with the Neag Comprehensive Cancer Center's extremely talented cancer researchers to rapidly convert data into actionable computer models of different cancers and clinical insights," said Neyarapally, Senior Vice President of Corporate Development at GNS. "We feel privileged to be working closely with Dr. Runowicz, an established leader in the fight against cancer."
About Gene Network Sciences
Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in
About The
The
SOURCE Gene Network Sciences, Inc.
Source: PR Newswire
Related Articles
- U.S. Naval Medical Research Center Proposed 'RESUS' Clinical Trial in Trauma Patients Remains on FDA Hold
- Cancer Researchers at Manhattan-Based St. Vincent's Comprehensive Cancer Center Discover Genes That Can Determine How Patients Respond to Pre-Leukemia Drug
- Yale Cancer Center Funds Phenoxodiol Study
- Researchers From Erasmus Cancer Center Validate the Clinical and Prognostic Utility of the HOXB13/IL17BR Ratio in Breast Cancer Patients
- Idaho Cancer Center to Offer Drug Trials
- MD Anderson Cancer Center Joins Protox Cancer Study
- Chicago Prostate Cancer Center First in World to Reach 100 Patient Implants Using Cesium-131(TM), Isotope From IsoRay Medical, Inc.
- Elekta: University of Florida Shands Cancer Center Gives New Hope to Spine Tumor Patients
- University of Florida Shands Cancer Center Gives New Hope to Spine Tumor Patients
- EDITORIAL: Research Arm Adds to Cancer Center's Impact
User Comments (0)

RSS Feeds